Fudan University

Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Kite, Business, Business administration, Patient, Research, DNA, Fudan University, Acquisition, NYU, MBA, Doctor of Philosophy, DDR, Master of Business Administration, Therapy, Drug development, Investment, RTW

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.

Key Points: 
  • CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.
  • Niall Martin, Chief Executive Officer of Artios, said: “We are delighted to welcome Chris, a prominent research analyst to our Board of Directors.
  • Chris Liu, Ph.D. Board Director of Artios, added: “RTW is now a top shareholder of Artios following the acquisition of Arix and the expansion of our equity interest, which reflects both our confidence and excitement in Artios’ innovative platform targeting broad aspects of the DNA damage response.
  • He currently serves on the board of NiKang Therapeutics, Oricell Therapeutics and Nuance Pharma as a Board Director or Observer.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

Retrieved on: 
Thursday, March 28, 2024
B-cell lymphoma, Plasma, Shanghai Cancer Center, Rituximab, Apoptosis, Leukemia, International Journal of Hematology, Patient, Hospital, Doxorubicin, Vincristine, Fudan University, CC3, Standard of care, Acute myeloid leukemia, Epidemiology, Biomedical Chromatography, Prednisone, Peripheral T-cell lymphoma, PARP, National Cancer Center, Therapy, MYC, BTK, Safety, BeiGene, CDK9, Cyclophosphamide, DLBCL, Canadian International Council, MCL1, Follicular lymphoma, Pharmaceutical industry

The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.

Key Points: 
  • The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.
  • This study will be the first combination trial conducted by a Chinese biotech to combine CDK9 inhibitor and BTK inhibitor targeting DLBCL.
  • The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively.
  • Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025, Leukemia & Lymphoma, 2021
    3.

Yunkang Announces 2023 Annual Results, Revenue Reaches RMB892 Million

Retrieved on: 
Monday, March 25, 2024
Diagnosis, University, Sun, Personalized medicine, Specialization, Infection, Genetics, ESG, Accounting, Patient, DSM-IV codes, Research, Hospital, Fudan University, Stock exchange, Policy, Marie Cassidy, AI, Cancer, Laboratory, Medicine, City, Social, Neoplasm, Pathology, Intellectual property, League, Nanchang University, Medical device

HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2023 (the "Reporting Period"). In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million. The Group's routine testing business achieved a healthy and steady year-on-year growth of 26.9% during the Reporting Period. Due to enhanced operational and management capabilities and improved cost control, the overall gross profit margin remained stable at 36.5%. The Group further improved its operational and management capabilities and strengthened its cash flow management, resulting in a significant improvement in net cash generated from operating activities as compared with last year. As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million. The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023. 

Key Points: 
  • In 2023, the Group continued to expand its business network and services across the country, the Group's revenue reached RMB891.5 million.
  • As at December 31, 2023, the Group's cash and cash equivalents amounted to RMB1,244.1 million.
  • The Board of Directors resolved to recommend the payment of a final dividend of HK$0.02 per share for the year ended December 31, 2023.
  • During the Reporting Period, the Group's investment in R&D amounted to RMB55.3 million, which increased as a percentage of operating revenue to 6.2% for the year ended December 31, 2023.

FinVolution Group Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

Retrieved on: 
Monday, March 18, 2024
Research, Chart, Growth, International, Fudan University, Acquisition, ADS, Credit, EMBA, Investment, Delinquent, Traction, GAAP, Calendar, Share repurchase, Marketing

SHANGHAI, March 18, 2024 /PRNewswire/ -- FinVolution Group ("FinVolution" or the "Company") (NYSE: FINV), a leading fintech platform, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Average loan size[10] was RMB9,044 for the fourth quarter of 2023, compared with RMB7,682 for the same period of 2022.
  • Number of new borrowers[16] for the fourth quarter of 2023 was 0.33 million, an increase of 2.1% compared with the same period of 2022.
  • Transaction volume[3] reached RMB2.25 billion for the fourth quarter of 2023, an increase of 64.2% compared with the same period of 2022.
  • Mr. Jiayuan Xu, FinVolution's Chief Financial Officer, continued, "Our strong full-year financial results speak for our outstanding strategic execution throughout 2023.

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Other Health, Health, General Health, Women, Pharmaceutical, Oncology, Research, Consumer, Science, Clinical Trials, Progression-free survival, Fudan University, Shanghai Cancer Center, ISD, PARP, ESGO, BRCA, HKEX, Platelet, OS, Gynecologic Oncology (journal), Ovarian cancer, SGO, Patient, Congress, Development, Niraparib, Pharmaceutical industry

“Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.

Key Points: 
  • “Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.
  • “We look forward to sharing the final OS findings from this study at both the 2024 ESGO and SGO conferences.
  • The final OS analysis was conducted after ≥ 50% of OS events occurred in the intent-to-treat population.
  • No new safety signals were identified during the long-term follow up period subsequent to the primary analysis.

Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results

Retrieved on: 
Tuesday, February 20, 2024
Other Health, Research, General Health, Oncology, Consumer, Medical Devices, Clinical Trials, Science, Women, Biotechnology, Medical Supplies, Health, OTCQB, Hospital, Cervical cancer, Fudan University, SMI, Physician, Shandong University, Chinese, Therapy, Statistics, NMPA, Pharmaceutical industry

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that a group of prominent cervical cancer doctors are in the final stages of completing the clinical data report that will be submitted for approval by the Chinese National Medical Products Administration (NMPA).

Key Points: 
  • Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that a group of prominent cervical cancer doctors are in the final stages of completing the clinical data report that will be submitted for approval by the Chinese National Medical Products Administration (NMPA).
  • The data quality assurance review team is being led by Dr. Sui Long, Director of the Gynecology Hospital at Fudan University and includes physicians from Qilu Hospital at Shandong University and two hospitals in Shanghai.
  • The quality assured data report is expected by the end of this month with final statistics from the study to be available early in March.
  • SMI’s CEO, Mr. Yaohua Li reported that “We already have pre-orders from multiple provinces in China for nearly 100 devices and thousands of disposables.

Grain Management Announces Promotions, Recognizing Corporate Excellence and Outstanding Performance

Retrieved on: 
Wednesday, January 24, 2024
Associate, Fudan University, Texas A&M University, Female, Operation, Tuck School of Business, David G. Booth, TMT, University, Business, IHeartMedia, Morgan Stanley, Strategic planning, Dartmouth College, Acquisition, LendingClub, Telecommunications, Communication, Media, Boston University, Growth, Management

WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Grain Management, LLC ("Grain"), a trusted solutions provider to the broadband and communications industry, announced today three senior-level investment team promotions.

Key Points: 
  • WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Grain Management, LLC ("Grain"), a trusted solutions provider to the broadband and communications industry, announced today three senior-level investment team promotions.
  • Grain said, "Without the outstanding leadership and performance of these individuals, the exceptional growth of our Firm and the success we have seen over the past year would not have been possible.
  • Ms. Berger joined Grain in 2019 as a Senior Associate after starting her career in investment banking and asset finance.
  • Along with Berger, Heidari, and Zhou, Grain made 15 additional promotions on its Investment and Operations & Administrations teams effective January 2024.

HOYA, a Leading Enterprise in Vision Care, Debuts at 2023 CIIE with Full Lifecycle Eye Health Management Solutions

Retrieved on: 
Tuesday, November 14, 2023
Associate, Attention, Pronoun, Near-sightedness, Hoya Corporation, Fudan University, Health, Consulate, Knowledge, Eye, Culture, Social responsibility, Patient, UV, China International Import Expo, Environment, Nursing

HOYA, a leading enterprise in vision care, debuts at 2023 China International Import Expo with full lifecycle eye health management solutions

Key Points: 
  • Their dedication to advancing vision healthcare worldwide drove them to consistently develop more advanced solutions for eye care professionals and patients globally.
  • With a high national prevalence of myopia, numbering 600 million affected citizens, China faces pressing eye care challenges.
  • At the same time, proper eye health management for China's rapidly growing elderly population is an important priority.
  • Myopia prevention and general eye health have rightly become issues of widespread public concern and attention in China.

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Retrieved on: 
Wednesday, December 13, 2023
Quality of life, Axitinib, Shanghai Cancer Center, Everolimus, RECIST, HKEX, Fudan University, Sintilimab, RCC, TTR, Patient, Safety, Pharmaceutical industry

HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“ HUTCHMED ”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.

Key Points: 
  • HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“ HUTCHMED ”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.
  • The study is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced RCC.
  • The primary endpoint is progression free survival (“PFS”) per RECIST 1.1 as assessed by blinded independent central review (BICR).
  • If favorable, the results would enable a New Drug Application submission to China’s National Medical Products Administration (“NMPA”).